A new report by British psychiatrist Dr.
David Bell has raised questions about the safety and efficacy of medical interventions for children experiencing gender dysphoria, which include puberty blockers and cross-sex hormones.
The review concluded that there is a lack of evidence to support these treatments, citing inconsistencies in psychological well-being, cognitive and bone development, and cardio-metabolic risk or fertility.
The Cass Review did not find any evidence supporting the claim that hormonal treatment reduced the risk of suicide among children with gender dysphoria.
Medical associations recommending medicalization of gender dysphoric children have remained largely silent about the report.
In contrast, some critics argue that there is an overemphasis on affirming a child’s stated gender identity without proper investigation into underlying psychological or psychiatric issues that may contribute to their feelings of dysphoria.
Dr.
Bell’s review has sparked a discussion among professionals in the field about whether medical interventions should be first-line treatment options for children with gender dysphoria, particularly given the potential long-term consequences and the lack of evidence supporting their efficacy and safety.